China’s healthcare security authorities are moving to loosen their grip on the pricing of newly approved, novel chemical drugs, a key part of proposed policies to streamline the government procurement of such medicines nationwide.
Drug makers will be allowed to set the initial listing prices of such medicines without government intervention, on the condition...








